BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GenFleet Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies GenFleet Therapeutics's drugs run
 \, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07554859-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GFH375: Phase 2 readout est. (NCT07554859)
DESCRIPTION:GFH375\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: GFH375 M
 onotherapy and Combination Therapy as First-Line Treatment for Advanced KR
 AS G12D-Mutant Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0755
 4859
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644559-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07644559)
DESCRIPTION:GFH375\, phase 2\, Pancreatic Ductal Adenocarcinoma.\nStudy: A 
 Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Can
 cer\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07644559
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659782-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07659782)
DESCRIPTION:GFH375\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung 
 Cancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07659782
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659795-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07659795)
DESCRIPTION:GFH375\, phase 2.\nStudy: A Phase 2 Study of VS-7375 in Patient
 s With KRAS G12D-Mutated Colorectal Cancer\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0765979
 5
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07262567-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 3 readout est. (NCT07262567)
DESCRIPTION:GFH375\, phase 3.\nStudy: Phase III Study to Compare GFH375 and
  Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Canc
 er\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07262567
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07259590-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:GFH375: Phase 1/2 readout est. (NCT07259590)
DESCRIPTION:GFH375\, phase 1/2.\nStudy: A Study of GFH375 Combined With Cet
 uximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G1
 2D Mutation\nEstimated primary completion: July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07259590
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198321-2492@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07198321)
DESCRIPTION:GFH276\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Sing
 le-Arm\, Open-Label\, Multicenter Phase I/II Clinical Study of GFH276 in P
 atients With RAS-Mutant Advanced Solid Tumors\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh2
 76#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7198321
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678593-2492@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07678593)
DESCRIPTION:GFH276\, phase 1/2.\nStudy: A Study of GFH276 Combined With Cet
 uximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Du
 ctal Adenocarcinoma (PDAC) Harboring RAS Mutation\nEstimated primary compl
 etion: November 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gfh276#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07678593
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2492@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:GFH276\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: This i
 s a Multicenter\, Open-label\, Phase I/II Study to Explore the Safety\, To
 lerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy of GFH276 in
  Patients With Advanced NSCLC Harboring a RAS Mutation.\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/gfh276#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07846358
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915921-2492@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07915921)
DESCRIPTION:GFH276\, phase 1/2.\nStudy: A Phase Ib/II Study of GFH276 in Co
 mbination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With
  RAS-mutant Metastatic Colorectal Cancer\nEstimated primary completion: 30
  April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh276#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07915
 921
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06500676-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:GFH375: Phase 1/2 readout est. (NCT06500676)
DESCRIPTION:GFH375\, phase 1/2.\nStudy: A Study of GFH375 in Patients With 
 Advanced Solid Tumors With KRAS G12D Mutations\nEstimated primary completi
 on: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh
 375#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06500676
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07784374-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:GFH375: Phase 2 readout est. (NCT07784374)
DESCRIPTION:GFH375\, phase 2.\nStudy: A Phase II Study of GFH375 Combined W
 ith GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Lo
 cally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS
  G12D Mutation\nEstimated primary completion: 31 August 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07784374
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913360-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:GFH375: Phase 3 readout est. (NCT07913360)
DESCRIPTION:GFH375\, phase 3.\nStudy: GFH375 Plus Cetuximab vs Investigator
 's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorecta
 l Cancer\nEstimated primary completion: November 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07913360
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GFH375: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:GFH375\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668752-2279@assetmemo.bio
DTSTAMP:20261121T005713Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:GFH375: Phase 3 readout est. (NCT07668752)
DESCRIPTION:GFH375\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lu
 ng Cancer With KRAS G12D Mutation\nEstimated primary completion: 30 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07668752
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
